Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

What Was Tested

The trial (phase 3) is built around Semaglutide.

This study is being conducted to see if semaglutide tablets can be used as a treatment to help people who are above a healthy weight range to lose weight.

Semaglutide tablets are a new medicine being tested to treat people living with excess body weight.

Participants will either get semaglutide or placebo once daily morning for 44 weeks.

It had two arms (groups): one (experimental) and Semaglutide Placebo (placebo comparator).

Participants will receive placebo tablets matched to semaglutide orally once daily for 44 weeks.

The registry classes the interventions as drug.

Who Took Part

The registry lists 200 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. Male or female, age greater than or equal to 18 years at the time of signing informed consent. Body mass index (BMI) of. Greater than or equal to 28.0 kilogram per meter square (kg/m\^2) or. History of at least one self-reported unsuccessful dietary effort to lose body weight.

The full record lists 9 inclusion and 5 exclusion criteria; among the exclusions: history of type 1 or type 2 diabetes; treatment with glucose-lowering agent(s) within 90 days prior to screening.

How the Study Was Run

The set-up was randomized, parallel-group and quadruple-blind.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

The Semaglutide group and the comparison group ran side by side rather than switching.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2023-05-30 with completion listed for 2025-01-16.

It ran at 16 sites in China (16).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Relative Change in Body Weight (time frame: From baseline (week 0) to end of treatment (week 44)).

It also tracked 25 secondary outcomes, for example Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite- CT) - Physical Function Domain, Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite- CT) - Total score, Change in Impact of Weight on Daily Activities Quesionnaire (IWDAQ) - Total Score, Change in Body Mass Index (BMI), Change in Waist Circumference and Change in Systolic Blood Pressure.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Semaglutide in 200 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.